NThe strength of this study is eradicating selection bias by enrolling all patients with new onset IBD. It utilized

NThe strength of this study is eradicating selection bias by enrolling all patients with new onset IBD. It utilized a nationally representative sample size of 23,982 biopsied and confirmed cases with a predictive value of 95%. The limitation of the study is the assumption that all prescribed and dispensed medications through the Prescribe Drug Register were used by the patient, which may falsify antibiotics therapy association with IBD. The observational case study did not permit measuring confounding factors, incident rates, and absolute risk. Additionally, the study concentrated on adults with new-onset IBD instead of including those with chronic disease.guyen and colleagues (2020) conducted a case study investigation to ascertain how antibiotic therapy is linked to Inflammatory Bowel Disease in the larger population. respone